IS8416A - Aðferð við framleiðslu á CCR-2 mótlyfi - Google Patents

Aðferð við framleiðslu á CCR-2 mótlyfi

Info

Publication number
IS8416A
IS8416A IS8416A IS8416A IS8416A IS 8416 A IS8416 A IS 8416A IS 8416 A IS8416 A IS 8416A IS 8416 A IS8416 A IS 8416A IS 8416 A IS8416 A IS 8416A
Authority
IS
Iceland
Prior art keywords
ccr
antagonist
production
Prior art date
Application number
IS8416A
Other languages
English (en)
Inventor
Cai Dongwei
Fleitz Fred
Ge Min
Hoerrner Scott
Javadi Gary
Jensen Mark
Larsen Robert
Li Wenjie
Nelson Dorian
Szumigala Elizabeth
Yang Lihu
Zhou Changyou
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS8416A publication Critical patent/IS8416A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS8416A 2003-10-27 2006-04-12 Aðferð við framleiðslu á CCR-2 mótlyfi IS8416A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51475403P 2003-10-27 2003-10-27
PCT/US2004/035294 WO2005044795A1 (en) 2003-10-27 2004-10-25 Process for the preparation of ccr-2 antagonist

Publications (1)

Publication Number Publication Date
IS8416A true IS8416A (is) 2006-04-12

Family

ID=34572776

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8416A IS8416A (is) 2003-10-27 2006-04-12 Aðferð við framleiðslu á CCR-2 mótlyfi

Country Status (11)

Country Link
US (1) US7361765B2 (is)
EP (1) EP1682500A1 (is)
JP (1) JP4551405B2 (is)
CN (1) CN101160286B (is)
AR (1) AR045875A1 (is)
AU (1) AU2004287810B2 (is)
BR (1) BRPI0415862A (is)
CA (1) CA2543250C (is)
IS (1) IS8416A (is)
TW (1) TWI294426B (is)
WO (1) WO2005044795A1 (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL376925A1 (pl) 2002-11-27 2006-01-09 Incyte Corporation Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny
US7393844B2 (en) * 2003-03-18 2008-07-01 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
AU2004287416C1 (en) * 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt
BRPI0417605B8 (pt) 2003-12-18 2021-05-25 Incyte Corp “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.
JP2007537264A (ja) 2004-05-11 2007-12-20 インサイト コーポレイション ケモカインレセプタのモジュレータとしての3−(4−ヘテロアリールシクロヘキシルアミノ)シクロペンタンカルボキサミド
US20130345254A1 (en) * 2011-03-17 2013-12-26 Anilkumar G. Nair Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
US8822460B2 (en) * 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CN104418769A (zh) * 2013-09-03 2015-03-18 苏州安尼康药物研发有限公司 一种化合物及其制备方法
US20180072945A1 (en) 2015-04-27 2018-03-15 Konica Minolta, Inc. Material for organic electroluminescent elements, organic electroluminescent element, display device and lighting device
PT3297438T (pt) 2015-05-21 2022-01-25 Chemocentryx Inc Moduladores de ccr2
CN105968055B (zh) * 2016-07-26 2018-08-28 中国科学院长春应用化学研究所 一种芳基嘧啶及其衍生物的制备方法
MA50665A (fr) 2017-09-25 2020-08-05 Chemocentryx Inc Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
JP2004506013A (ja) * 2000-08-17 2004-02-26 メルク エンド カムパニー インコーポレーテッド シクロペンチル系ケモカイン受容体活性調節剤
BR0209687A (pt) * 2001-05-15 2004-09-14 Du Pont Método de controle de doenças vegetais, composto e composição
CA2483752C (en) * 2002-04-29 2011-03-29 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
AU2004287416C1 (en) * 2003-10-27 2010-09-09 Merck Sharp & Dohme Corp. CCR-2 antagonist salt

Also Published As

Publication number Publication date
CA2543250A1 (en) 2005-05-19
US20070135475A1 (en) 2007-06-14
JP4551405B2 (ja) 2010-09-29
CN101160286A (zh) 2008-04-09
EP1682500A1 (en) 2006-07-26
JP2007509944A (ja) 2007-04-19
TWI294426B (en) 2008-03-11
CN101160286B (zh) 2012-07-04
WO2005044795A8 (en) 2006-06-22
BRPI0415862A (pt) 2007-01-09
TW200530233A (en) 2005-09-16
WO2005044795A1 (en) 2005-05-19
AU2004287810B2 (en) 2011-01-06
AR045875A1 (es) 2005-11-16
US7361765B2 (en) 2008-04-22
AU2004287810A1 (en) 2005-05-19
CA2543250C (en) 2011-03-29

Similar Documents

Publication Publication Date Title
PT1398327E (pt) Método de produção de derivados de hidroxialquil-amido
CY2015015I1 (el) Παραγωγη τιακουμυκινης
NO20053796D0 (no) Process for the production of particles
DE602005026757D1 (de) Tonerherstellungsmethode
IL175148A0 (en) Method for the production of fluoromethyl-substituted heterocycles
IS8122A (is) Aðferð til að framleiða N-útskipt 2-sýanópýrrólídín
PL371629A1 (pl) Sposób wytwarzania kombrestatyn
DE602004021052D1 (de) Herstellungsverfahren von Xylylendiamin
DE602004003115D1 (de) Tonerherstellungsverfahren
ATE465155T1 (de) Verfahrensherstellung von ethern
IS8333A (is) Aðferð við framleiðslu á THIP
ATE359703T1 (de) Aquakulturverfahren
DE60326321D1 (de) Herstellungsverfahren von Farbstoffen
NO20035626D0 (no) Metode
IS2894B (is) Framleiðsla sómatóstatínpeptíða
DE602004024308D1 (de) Immunchromatographisches verfahren
NO20035401D0 (no) Metode
GB0514455D0 (en) Method of making structural members
DE602005011294D1 (de) Verbessertes verfahren zur herstellung von mirtazapin
NO20054532D0 (no) Fremgangsmater for a forhindre glukonoylering av proteiner
ITRE20030116A1 (it) Metodo per la fabbricazione di piastrelle dotate di
NO20035692D0 (no) Produksjonsmetode
ITFI20030052A1 (it) Metodo per la produzione di argille organofile
FI20021421A0 (fi) Valmistusmenetelmä
ITAN20030003A1 (it) Metodo per la realizzazione di caldaie per la produzione